Loading provider…
Loading provider…
Hematology & Oncology Physician in San Diego, CA
NPI: 1073888657Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Mobile
Get MD PHD Mina's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2012 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
2014 - 2017
Kaiser Permanente Northern California (Oakland)
Residency • Internal Medicine
2011 - 2014
UC San Diego School of Medicine
medschool.ucsd.edu
Medical School
Until 2011
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 122 | 469 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 88 | 185 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 79 | 79 |
| 4 | J7050Infusion, normal saline solution , 250 cc | 38 | 145 |
| 5 | 96523Irrigation of implanted venous access drug delivery device | 26 | 39 |
Population pharmacokinetics of siltuximab: impact of disease state.
Authors: Nikanjam, Mina, Yang, Jin, Capparelli, Edmund V
Journal: Cancer Chemother Pharmacol
Publication Date: 2019-09-03
Nectin-4 expression patterns and therapeutics in oncology.
Authors: Sariah Liu
Journal: Oncotarget
Lead Sponsor: Replimune Inc.
Collaborators: Regeneron Pharmaceuticals
Intervention / Treatment: DRUG: Cemiplimab, BIOLOGICAL: RP1
Lead Sponsor: Gregory Daniels
Intervention / Treatment: DRUG: IL-2 and Nivolumab
Lead Sponsor: Gregory Daniels
Intervention / Treatment: DRUG: IL-2 and Nivolumab